Wall Street brokerages forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Sangamo Therapeutics’ earnings. The lowest EPS estimate is ($0.24) and the highest is $0.07. Sangamo Therapeutics posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year over year growth rate of 13.3%. The business is expected to report its next earnings results after the market closes on Thursday, November 8th.
According to Zacks, analysts expect that Sangamo Therapeutics will report full-year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.42). For the next financial year, analysts anticipate that the firm will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.06) to ($0.44). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business had revenue of $21.42 million during the quarter, compared to analysts’ expectations of $21.43 million. During the same quarter in the prior year, the firm earned ($0.17) EPS. Sangamo Therapeutics’s revenue for the quarter was up 159.6% compared to the same quarter last year.
A number of equities research analysts have commented on the company. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. ValuEngine upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 1st. Zacks Investment Research downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 10th. Guggenheim assumed coverage on Sangamo Therapeutics in a research report on Tuesday, October 9th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Wedbush restated a “hold” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $21.00.
In other news, Director H Stewart Parker acquired 2,000 shares of the company’s stock in a transaction dated Friday, September 7th. The stock was acquired at an average cost of $13.52 per share, with a total value of $27,040.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $14.17, for a total value of $70,850.00. The disclosure for this sale can be found here. Insiders sold 25,000 shares of company stock valued at $363,700 over the last ninety days. Insiders own 1.20% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Sangamo Therapeutics by 20.8% in the second quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock valued at $114,780,000 after buying an additional 1,391,067 shares in the last quarter. Wasatch Advisors Inc. grew its stake in shares of Sangamo Therapeutics by 9.9% in the second quarter. Wasatch Advisors Inc. now owns 4,058,167 shares of the biopharmaceutical company’s stock valued at $57,626,000 after buying an additional 365,186 shares in the last quarter. Northern Trust Corp grew its stake in shares of Sangamo Therapeutics by 21.0% in the second quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock valued at $18,286,000 after buying an additional 223,870 shares in the last quarter. Nexthera Capital LP grew its stake in Sangamo Therapeutics by 35.7% during the 2nd quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock worth $15,150,000 after purchasing an additional 280,538 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Sangamo Therapeutics by 12.7% during the 3rd quarter. Wells Fargo & Company MN now owns 890,234 shares of the biopharmaceutical company’s stock worth $15,089,000 after purchasing an additional 100,253 shares in the last quarter. 64.01% of the stock is owned by institutional investors and hedge funds.
NASDAQ:SGMO opened at $13.87 on Tuesday. Sangamo Therapeutics has a 52 week low of $11.60 and a 52 week high of $27.50. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -19.81 and a beta of 3.21.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
See Also: What is a Reverse Stock Split?
Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.